Diabetes is an umbrella term for three primary conditions: type 1 diabetes, type 2 diabetes, and gestational diabetes. According to guidelines established by experts in the field, there are multiple stages of diabetes, each of which are defined by physiological changes within the body.

In this article, well explore the stages of type 1 and type 2 diabetes as defined by diabetes experts, as well as information about long-term diabetes management.

Within the past decade, professional organizations, like the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE), have created guidelines that outline the various stages of diabetes development.

According to the literature on these guidelines, understanding the various stages of diabetes can allow physicians and patients to take a more comprehensive approach to preventive care and disease management.

Below, weve outlined the various stages of beta cell dysfunction, type 1 diabetes, and type 2 diabetes, as established by current experts in the field of diabetes research.

In 2015, the ADA released a joint statement with the JDRF and Endocrine Society outlining the various stages of type 1 diabetes. Using the guideline below, clinicians can more easily diagnose this condition at an earlier stage, even when symptoms might not be present.

Its important to note that type 1 diabetes is an autoimmune disease where the immune system attacks and destroys beta cells in the pancreas, which are responsible for producing insulin.

In this stage, genetic analysis can help identify underlying genotypes that are commonly associated with type 1 diabetes.

According to the research, a specific region on chromosome six called the HLA region is associated with up to 50 percent of the risk for developing this condition. Other factors, like having a sibling or close relative with type 1 diabetes, can also increase disease risk.

In this stage, at least one diabetes-related autoantibody is present in the blood. At this point, these autoantibodies have already begun to attack the beta cells in the pancreas. But blood sugar levels still remain within the normal range, and no symptoms are present.

In this stage, at least two or more diabetes-related autoantibodies are present in the blood. As the beta cells continue to be destroyed by the immune system, a lack of insulin leads to rising blood sugar levels due to glucose intolerance. Although beta cell dysfunction is more serious at this stage, there are still no symptoms yet.

In this stage, theres a significant loss of beta cells due to autoimmunity and symptoms are present, resulting in a type 1 diabetes diagnosis. During this stage, the symptoms of type 1 diabetes may include:

In 2018, the AACE created the dysglycemia-based chronic disease (DBCD) multimorbidity care model. Much like the previous guidelines above from 2015, the DBCD care model helps clinicians take preventative steps to reduce type 2 diabetes complications.

This stage, defined as insulin resistance, is where muscle, fat, and liver cells become resistant to insulin and have trouble bringing glucose into the cell. But the pancreas compensates for this by producing more insulin, which helps keep blood sugar levels within normal range.

In this stage, also known as prediabetes, cells become so insulin resistant that the extra insulin isnt enough to lower blood sugar levels back to normal. In some cases, beta cell dysfunction may also be present. During this stage, blood glucose levels remain higher than normal, but not high enough to be classified as diabetes.

In this stage, blood sugar levels remain abnormally high, leading to a diagnosis of type 2 diabetes. Both insulin resistance and beta cell dysfunction can lead to high blood sugar levels in type 2 diabetes. Without treatment, these elevated levels can cause long-term damage to the body.

In this stage, vascular complications can occur as a result of high blood sugar. As blood sugar levels remain high, damage can occur within the vascular system, leading to potential complications like:

While end-stage diabetes isnt a commonly used term, diabetes can lead to whats known as end-stage diabetic complications, or advanced complications. In people with diabetes, advanced complications, like end-stage renal disease, occur after many years of living with diabetes.

A study from 2019 found that microvascular complications from diabetes, like nephropathy, increase risk for cardiovascular events and death in people with type 1.

While theres no cure for diabetes, it can be managed through the appropriate treatment, which may include medications, dietary changes, and lifestyle interventions.

Although it can feel overwhelming to manage a chronic health condition like diabetes, your healthcare team is there to help you create a diabetes treatment plan that works best for you.

If youre concerned about managing your diabetes, the first step is to reach out to your doctor or care team to create a diabetes treatment plan. Depending on your diagnosis and personal needs, your treatment plan may include reaching out to:

According to experts in the field of diabetes research, diabetes staging plays an important role in the prevention, diagnosis, and treatment of diabetes. Understanding the various stages of both type 1 and type 2 diabetes allows physicians and patients to see the progression of the disease so that treatment and long-term management can be improved.

If youve been diagnosed with diabetes, its important to stay educated about your condition so that you can more easily manage it in the long-term.

Read the rest here:
Stages of Diabetes: Stages, Symptoms, and Treatments - Healthline

The relationship between type 2 diabetes and alcohol is complex. When people with this condition drink alcohol, it comes with risks. However, it does not mean people with type 2 diabetes cannot drink alcohol. The risks depend on how much alcohol a person consumes, as well as the type.

Diabetes is very common. According to the National Diabetes Statistics Report 2020, 34.2 million people in the United States had diabetes in 2018. The percentage of the population with diabetes increases according to age, reaching 26.8% in adults aged 65 and older.

Moderate alcohol consumption does not raise the risk of type 2 diabetes; however, heavy consumption might.

Overall, alcohol consumption leads to less predictable blood sugar levels, and this can be a risk.

Keep reading to learn more about how alcohol affects people with diabetes, including types of alcohol and how alcohol may cause hypoglycemia, or low blood sugar levels.

Learn more about hypoglycemia here.

Alcohol does not cause diabetes. However, according to American Diabetes Association (ADA), heavy consumption and zero consumption increase the risk. The ADA also states that a drink or two may improve insulin sensitivity and sugar management.

A 2015 meta-analysis reviewed 38 cohort studies to determine whether alcohol is a risk factor for diabetes. It found moderate consumption appeared to offer some protection against the condition in women and Asian populations, while heavy consumption raised the risk in almost all groups.

Because even moderate alcohol consumption can adversely many aspects of health, the negatives seem to outweigh the positives. More research must continue into this area.

Learn more about how alcohol affects blood sugar levels in diabetes.

The ADA does not forbid a person with diabetes from consuming alcohol, but they do not advise it either. If someone with diabetes chooses to drink alcohol, the ADA recommends limiting consumption to a moderate intake. This translates to one drink per day for females and up to two per day for males.

However, the ADA adds that if an individual with diabetes does not already drink, this does not mean they should start.

Below are some detrimental effects of alcohol on diabetes:

Doctors advise some people with diabetes to abstain from alcohol for reasons unrelated to their blood sugar. The Department of Veterans Affairs (DVA) warns that individuals with diabetes may have other conditions that alcohol could affect. In addition, certain non-diabetic medications do not mix well with alcohol.

Because alcohol is highly addictive and research links heavy consumption to an array of adverse health effects, avoiding the beverage is the healthiest choice for anyone.

The bottom line is that any person with diabetes who wishes to consume alcohol should first discuss it with a doctor.

Learn more about the risks of chronic heavy drinking here.

The below information can help someone adhere to the one-drink-per-day limit for females and the two-drinks-per-day limit for males.

These amounts comprise one standard drink:

When individuals calculate how much alcohol they can consume while staying within the recommended guidelines, they should know that some common alcoholic beverages contain more than one standard serving of a drink. For example:

A person should avoid sweetened liquor or alcohol mixed with sodas or punch.

Learn more about how alcohol affects health here.

The biggest concern associated with alcohol for someone with diabetes involves the risk of hypoglycemia, which is low blood sugar. Hypoglycemia is when blood sugar falls below 70 mg/dL.

Alcohol consumption can decrease blood sugar, as can some diabetes medications. If these decreases occur at the same time, it can cause hypoglycemia.

This happens because the liver stores carbohydrates and releases them into the blood between meals and overnight to stabilizes blood sugar. The liver is also responsible for breaking down alcohol so the kidneys can flush it out of the body.

The problem is that the liver cannot perform both functions at the same time. When a person consumes alcohol, the liver begins to break it down. When it is busy doing this, it does not release stored carbohydrates to maintain blood sugar, meaning that blood sugar levels can drop to dangerous levels.

Exercise can also increase the risk of hypoglycemia when coupled with other factors, such as drinking alcohol. Doctors strongly encourage people with diabetes to engage in regular physical activity because it reduces blood sugar. However, exercising, drinking alcohol, and taking blood sugar-lowering medication could cause hypoglycemia.

Symptoms of hypoglycemia include:

The risk of hypoglycemia is why experts advise people with diabetes not to drink alcohol if their blood sugar is already low. If a person chooses to drink, they should always eat at the same time and include carbohydrates, such as fruits, vegetables, or grains, in their meal.

They should also keep a closer watch on their blood sugar so they can quickly react if levels fall too low.

Learn more about testing glucose levels here.

The CDC list the below risk factors for developing type 2 diabetes:

Learn more about the risk factors for type 2 diabetes here.

Type 2 diabetes and alcohol is not always a beneficial combination. While moderate alcohol consumption lowers blood sugar, heavy consumption is harmful to diabetes and other aspects of health.

The ADA neither forbids nor advises people to drink alcohol. However, the organization recommends that females with diabetes limit their consumption to one drink per day and males limit their consumption to two drinks per day.

If someone chooses to consume alcohol, they should have food with it and keep a close watch on their blood sugar.

Most importantly, if individuals wish to engage in moderate drinking, they should first discuss it with their doctor.

Read more from the original source:
Type 2 diabetes and alcohol - Medical News Today

A class of type 2 diabetes drugs is associated with reduced brain plaque and better cognitive scores in people with Alzheimers disease, a new study suggests. The findings appear in theAugust 2021 issue ofNeurology.

The drugs called dipeptidyl peptidase4, or DPP-4, inhibitors are prescribed to people with type 2 diabetes to help lower blood sugar. Examples of DPP-4 inhibitors that are approved by the Food and Drug Administration are Januvia (sitagliptin), Onglyza (saxagliptin), Tradjenta (linagliptin), and Nesina (alogliptin).

People with diabetes have been shown to have a higher risk of Alzheimer's disease, possibly due to high blood sugar levels, which have been linked to the buildup of amyloid beta in the brain, said senior study author Philhyu Lee, MD, PhD, of Yonsei University College of Medicine in Seoul, South Korea, in a statement.

Not only did our study show that people taking dipeptidyl peptidase-4 inhibitors to lower blood sugar levels had less amyloid in their brains overall, it also showed lower levels in areas of the brain involved in Alzheimer's disease, Dr. Lee said in the statement.

At the start of the study, researchers gave 282 participants with Alzheimers disease brain scans to measure the accumulation of amyloid plaque, or abnormal protein deposits in the brain that are associated with memory decline. They also administered cognitive tests and repeated assessments roughly every 12 months over a median follow-up period of 2.5 years. The study included three cohorts: 70 people with diabetes treated with DPP-4 inhibitors; 71 people with diabetes who didnt take DPP-4 inhibitors; and 141 people without diabetes.

Brain scans showed that people on DPP-4 inhibitors had a lower amyloid burden than either of the other two groups in the study after researchers adjusted for age, sex, education, cognitive status, and a mutation of the APOE-4 gene associated with Alzheimers disease.

Individuals with diabetes also experienced smaller declines in global cognition and memory recall when they took DDP-4 inhibitors than when they didnt use these drugs.

RELATED: Why Some Researchers Are Calling Alzheimers Disease a Type 3 Diabetes

Activities on the cognitive test repeated during the study included tasks like counting backwards from 100 by sevens or copying a picture. Scores on the test, called the Mini-Mental State Examination (MMSE), ranged from 0 to 30, with higher scores indicating better cognitive function. The average annual decline in scores was 0.87 points for people with diabetes on DPP-4 inhibitors, 1.65 points for people with diabetes not on these drugs, and 1.48 points for people without diabetes.

Id suspect that by lowering amyloid there might be some effect on reducing memory decline, says Glen Finney, MD, the director of the memory and cognition program and a neurology professor at the Geisinger Commonwealth School of Medicine in Scranton, Pennsylvania.

A bigger study would help to see if that were the case, adds Dr. Finney, who wasnt involved in the study.

Beyond its small size, the study was limited because researchers lacked data on baseline blood sugar levels, which would be needed to help determine what role the changes in blood sugar over time might play in the results.

The study also didnt use brain scans to look for changes in amyloid accumulation over time. In addition, the MMSE tests administered multiple times, while considered an accurate way to track changes in cognitive function, dont offer the same precision as more comprehensive cognitive assessments such as neuropsychological testing, Lee and colleagues note in their study.

RELATED: COVID-19 Pandemic Fuels Rise in Alzheimers Deaths

Yet previous studies have also linked diabetes medications to better outcomes for people with Alzheimers disease, says Finney.

Over the decades thereve been hints in research that at least some Alzheimers disease cases relate to glucose and diabetes, and may be helped by treatments that are used for diabetes, Finney says. This is another example of a treatment, DPP-4 inhibitors, that is showing some signal of that.

One study published in August 2020 in Alzheimers & Dementia, for example, looked at memory test results for 1,192 people with type 2 diabetes who didnt have cognitive impairment and for 807 people with type 2 diabetes who had Alzheimers disease. This study found that DPP-4 inhibitors were linked with a slower deterioration in memory among those with Alzheimers disease. It also found that Glucophage (metformin), another type of medicine to lower blood sugar, was associated with slower memory decline among carriers of an APOE-4 gene mutation linked to Alzheimers disease.

An earlier study, published in June 2018 in the Annals of Translational Medicine, reviewed preclinical lab work and human studies to date on the effect of DPP-4 inhibitors on cognition and found that DPP-4 inhibitors were protective against further memory decline in people with diabetes who had mild cognitive impairment.

DPP-4 inhibitors are used to improve the regulation of blood sugar, which preclinical studies suggest may be associated with increased amyloid accumulation in the brain, says Jill Morris, PhD, assistant professor of neurology at the University of Kansas Medical Center in Kansas City, who wasnt involved in the latest study.

Bringing blood sugar levels back to normal could potentially normalize amyloid processing, Dr. Morris says.

RELATED: Why Black Americans May Be Less Likely to Start Newer Type 2 Diabetes Drugs

Randomized clinical trials are needed to answer this question and to determine if DPP-4 inhibitors can directly cause slower cognitive decline, Morris adds. Thats because DPP-4 inhibitors are often prescribed for people whose blood sugar is not ideally managed and who dont respond to other diabetes medicines. As a result, people on DPP-4 inhibitors may have higher blood sugar levels when they initiate treatment than patients who dont use these drugs this was the case for the patients in the latest study.

Randomized clinical trials are needed to evaluate the effectiveness of DPP-4 inhibitors to slow cognitive decline in individuals both with and without diabetes, Morris says.

While all people with type 2 diabetes should still take medications as needed to lower their blood sugar, including DPP-4 inhibitors if theyre prescribed, people shouldnt be on this medication just because they think it might help prevent dementia, Finney says.

It is too early to make any decisions on taking DPP-4 inhibitors solely for hope of slowing Alzheimers disease, but if you have a good reason otherwise to be on a DPP-4 inhibitor, then we can hope you may get an added benefit, Finney says. But whether or not to use a DPP-4 inhibitor should be based on what is best for your diabetes control.

RELATED: What Are the Complications of Type 2 Diabetes, and How Can You Avoid Them?

Read this article:
Diabetes Drug Tied to Slower Cognitive Decline in Alzheimer's - Everyday Health

New research Is sounding the alarm on increased rates of gestational diabetes among first-time mothers in the US.

Conducted by investigators from Northwestern University, Kaiser Permanente, and the Centers for Disease Control and Prevention, the cross-sectional analysis of data from 12.6 million singleton births suggests the rate of gestational diabetes has increased from 47.6 per 1000 live births in 2011 to 63.5 per 1000 live births in 2019, with increases in prevalence observed across all racial and ethnic subgroups included in the analysis.

Given that gestational diabetes is associated with increased short-term and long-term risks for individuals and their offspring, the observed trends and disparities may portend a greater burden of future cardiometabolic disease, wrote investigators.

With the increased risk of Cardiometabolic conditions associated with gestational diabetes widely recognized, a team of investigators led by Sadiya Khan, MD, MSc, assistant professor at Northwestern University Feinberg School of Medicine, conducted the present study to develop a greater understanding of contemporary trends in the rate of gestational diabetes among individuals at first live births between 2011 and 2019. To do so, investigators designed their study as a serial cross-sectional analysis of information from the National Center for Health Statistics (NCHS).

From the NCHS, investigators identified 12,610,235 individuals aged 15-44 years with singleton live birth from 2011-2019. For the purpose of analysis, these patients were stratified into the following groups: Hispanic/Latina, non-Hispanic Asian/Pacific Island, non-Hispanic Black, and non-Hispanic White. Of note, the Hispanic/Latina group included those identifying Central and South American, Cuban, Mexican, and Puerto Rican and the non-Hispanic Asian/Pacific Islander group included those identifying as Asian Indian, Chinese, Filipina, Japanese, Korean, and Vietnamese.

The primary outcomes of interest for the analysis were the age-standardized rates of gestational diabetes per 1000 live births and respective mean annual percent change and rate ratios of gestational diabetes among the aforementioned groups and subgroups relative to those in the non-Hispanic White group.

The 12,610,235 individuals included in the analysis had a mean age of 26.5 (SD, 5.8) years, 21% were Hispanic/Latina, 8% were non-Hispanic Asian/Pacific Islander, 14% were non-Hispanic Black, and 56% were non-Hispanic White. Overall, the age-standardized gestational diabetes rates increased from 47.6 (95% CI, 47.1-48.0) per 1000 live births in 2011 to 63.5 (95% CI, 63.1-64.0) per 1000 live births in 2019, which represents a mean annual percent change of 3.7% (95% CI, 2.8-4.6%) per year.

In analyses of subgroups based on race, increases were observed across all groups from 2011 to 2019. Investigators noted rates were greatest among Asian Indian patients, with a rate of 129.1 (95% CI, 100.7-104.7) per 1000 live births. Investigators also pointed out rates were greatest among Puerto Rican (75.8 per 1000 live births [95% CI, 71.8-79.9]) patients than any other Hispanic/Latina subgroup.

In an editorial comment, CamillePowe,MD, and EbonyCarter,MD, MPH, express their concern over the rising rates of gestational diabetes and potential racial and ethnic barriers to care.

The study by Shah et aldocuments a concerning trend of increasing gestational diabetes rates over the past decade, as well as persistent racial and ethnic inequities in gestational diabetes prevalence. Because of the strong links between glucose intolerance during pregnancy and future diabetes, these observations ominously foreshadow a potential future increase in diabetes incidence wrote Powe and Carter.

This study, Trends in Gestational Diabetes at First Live Birth by Race and Ethnicity in the US, 2011-2019, was published in JAMA.

Visit link:
Rates of Gestational Diabetes on the Rise Among First-Time Mothers in the US - Endocrinology Network

Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin, a hormone that regulates blood sugar, or when the body cannot effectively use the insulin it produces.

Type 2 diabetes, once known as non-insulin dependentdiabetesor adult-onset diabetes, is the most common form of diabetes, according to the U.S. Centers for Disease Control and Prevention (CDC). The number of people worldwide with diabetes nearly quadrupled from 108 million in 1980 to 422 million in 2014, and it continues to grow.

In the U.S. alone, the prevalence of diabetes has risen dramatically and, today, more than 34 million people have the disease. One of the biggest increases in recent years has been among men, the CDC says. Of the 13 million U.S. men with diabetes, roughly 95 percent have type 2 diabetes.

Unlike people withtype 1 diabetes, people withtype 2 diabetesmake insulin, says Sol Harari, M.D., a family medicine physician with Baptist Health Primary Care. But its not enough, or their body doesnt recognize theinsulinand use it the way it should. This is called insulin resistance.

Although it is far more common than type 1 diabetes, type 2 diabetes is less well understood, according to Dr. Harari, and is probably caused by the confluence of several things and not one single problem. Type 2 diabetes can run in families, but the exact nature of how its inherited or the identity of a single reason for it in your genes isnt known, he says. The risk fortype 2 diabetesusually goes up with age, he adds. People who dont have other risk factors for the condition should start getting tested after age 45.

Diabetes can cause a cascading array of other health problems, Dr. Harari says. When there isnt enough insulin or the insulin isnt used as it should be,sugar or glucose cant get into your cells to be used for fuel. When sugar builds up in yourblood, your cells dont work the way they should.

Symptoms of type 2 diabetes can differ from person to person but according to Dr. Harari they commonly include:

Other problems can also be linked to the buildup of sugar in the blood, Dr. Harari says, including:

Dehydration: The buildup of sugar in the blood can make you urinate more, as your kidneys try to clear the sugar from your body. Frequent urination means youre losing a lot of fluid, which can lead to dehydration.

Hyperosmolar nonketoticdiabetic coma: When a person with type 2 diabetes becomes severely dehydrated and doesnt drink enough fluids to make up for the fluid losses, they may develop this life-threatening complication.

Damage to the body: Over time, highsugar levelsin the blood can damage nerves and small blood vessels of theeyes, kidneys andheart,and also put someone at risk of atherosclerosis, or hardening of the largearteries, whichcan cause aheart attackorstroke.

Dr. Harari reminds patients that anybody can get type 2 diabetes. However, he says the risk tends to be highest in people who:

In addition, Dr. Harari says, older people are more likely to get diabetes because aging makes the body less tolerant of sugars.

If yourdoctor suspects you may have type 2 diabetes, they will first check for signs of it in your blood, looking for high blood sugar levels). They may also look for sugar or ketone bodies in yoururine, says Dr. Harari. Tests used to diagnose type 2 diabetes include a fasting plasma glucose test and a casual plasma glucose test.

Dr. Harari cautions that if you have type 2 diabetes and arent controlling it well, you could develop serious and even life-threatening complications, including:

Diabetes is one of the most preventable diseases, says Dr. Harari. Studies have shown that 90 percent of all type 2 diabetes cases could be prevented, or significantly delayed, simply by eating healthier and getting enough physical activity.

In one study cited by Dr. Harari, researchers followed 3,234 people who wereconsidered at risk of developing diabetes because they were overweight and had higher blood glucose levels. Those who participated in a program ofexerciseand diet geared to losing excessweight in this case, an average of 15 pounds lowered theirrisk of diabetesby close to 60 percent.

Those over the age of 60 were able to cut their risk by more than 70 percent and these were people who already had a highrisk of diabetes, notes Dr. Harari. The lesson here is, stay active, keep your weight in the normal range and youll probably never get diabetes.

A diabetes diagnosis isnt a death sentence, assures Dr. Harari. In some cases, lifestyle changes can keep the disease entirely under control, he says. Still, many people with diabetes need to take oral medications that lower blood sugar levels. When these arent enough to do the job, insulin may be necessary, sometimes along with oral drugs. Dr. Harari notes that the FDA has recently approved several new drugs that work with insulin to improveblood sugarmanagement. Although treatment has improved, controlling diabetes remains a challenge, which is why we focus on prevention.

Tags: Baptist Health Primary Care, diabetes, men's health, Sol Harari M.D., type 2 diabetes

Read this article:
Expert Shares What Men Need to Know About Type 2 Diabetes - Baptist Health South Florida

NEW YORK, Aug. 16, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP), (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Diabetes, Obesity, and Metabolism, has published an original article titled "Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) in patients with type 2 diabetes mellitus - A randomized placebo-controlled trial" authored by Dr. Roy Eldor, Dr. Joel Neutel, Kenneth Homer and Oramed's Chief Scientific Officer, Dr. Miriam Kidron.

Oramed Pharmaceuticals Logo

The article presents the results of a trial that assessed the safety and efficacy of Oramed's lead drug candidate ORMD-0801 in type 2 diabetes (T2DM). The trial met its primary endpoint and found that in patients with T2DM, bedtime ORMD-0801 curbed increases in night-time glycemia, 24-hour glycemia, and HbA1c without increasing the risk of hypoglycemia or safety events as compared to the control arm.

"I'm proud and excited that this paper, exploring the interesting and important results of Oramed's Phase 2 study of oral insulin has been published by Diabetes, Obesity and Metabolism," said Roy Eldor, M.D. Ph.D., Director, Diabetes Unit, Institute of Endocrinology, Metabolism & Hypertension, Tel-Aviv Sourasky Medical Center, and a member of Oramed's Scientific Advisory Board.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule.

Story continues

For more information, please visit http://www.oramed.com.

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the potential efficacy and safety of ORMD-0801, the ability of Oramed to transform the treatment of diabetes and the potential of ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, historic results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Logo - https://mma.prnewswire.com/media/647544/Oramed_Pharmaceuticals_Logo.jpg

Company ContactJosh Hexter +1-844-9-ORAMEDjosh@oramed.com

Cision

View original content:https://www.prnewswire.com/news-releases/oramed-announces-publication-of-oral-insulin-study-in-peer-reviewed-journal-diabetes-obesity-and-metabolism-301355754.html

SOURCE Oramed Pharmaceuticals Inc.

See the article here:
Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism - Yahoo Finance